Loading...
Loading...
Browse all stories on DeepNewz
VisitWhat will Finch Therapeutics' quarterly revenue for Q4 2024 be?
Below $10 million • 25%
$10 million to $20 million • 25%
$20 million to $30 million • 25%
Above $30 million • 25%
Official financial statements
Finch Therapeutics Wins $26 Million Legal Judgment, Stock Soars 350%
Aug 11, 2024, 01:45 AM
Finch Therapeutics (FNCH), a microcap company, has been awarded a legal judgment totaling $26 million, including $25 million in damages and approximately $800,000 in royalties from ITD Rebyota sales. This outcome is significant for the company, which had a market cap of $6 million and cash reserves of around $15 million. The legal victory is expected to boost the company's cash position to over $40 million. The stock, which was valued at less than $1 with a market cap of $1.5 million as of June 2, has seen a substantial increase, rising by approximately 350% since the announcement of the legal judgment. This development marks a notable turnaround for Finch Therapeutics, potentially altering market perceptions of its financial stability.
View original story
Less than 50% • 25%
50% to 100% • 25%
100% to 200% • 25%
More than 200% • 25%
Below $1 million • 25%
$1 million to $5 million • 25%
$5 million to $10 million • 25%
Above $10 million • 25%
Below $2.4 billion • 25%
$2.4 billion to $2.5 billion • 25%
$2.5 billion to $2.6 billion • 25%
Above $2.6 billion • 25%
Above $1.5B • 25%
Between $1.2B and $1.5B • 25%
Between $1.0B and $1.2B • 25%
Below $1.0B • 25%
Below $100 million • 25%
$100-150 million • 25%
$150-200 million • 25%
Above $200 million • 25%
Yes • 50%
No • 50%
Below expectations • 25%
Meets expectations • 25%
Exceeds expectations • 25%
Significantly exceeds expectations • 25%
Less than $300M • 33%
$300M - $500M • 33%
More than $500M • 33%
Below $50 million • 25%
$50 million to $100 million • 25%
$100 million to $150 million • 25%
Above $150 million • 25%
Below $25 billion • 25%
$25-30 billion • 25%
$30-35 billion • 25%
Above $35 billion • 25%
More than 20% increase • 25%
10%-20% increase • 25%
0%-10% increase • 25%
Decrease • 25%
No • 50%
Yes • 50%
Underperform • 25%
Match sector performance • 25%
Slightly outperform • 25%
Significantly outperform • 25%